The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today reported financial results for ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter ...

PDS Biotechnology Corp (PDSB) reports reduced net loss and strategic clinical trial progress, despite ongoing financial hurdles.

Precision Oncology market is set for strong growth through 2035, fueled by genomic advances, rising cancer cases, and increased use of targeted therapies.